Physician Views snap-poll: How does AbbVie's Skyrizi stack up?

AbbVie's post-Humira strategy reached a key inflection point this week with US approval of Skyrizi, an IL-23 inhibitor, for the treatment of moderate-to-severe plaque psoriasis.

The market for novel biologic therapies is sizeable and continues to grow; Novartis' Cosentyx - which utilises a different mechanism targeting IL-17 - is on track to deliver over $3 billion in global sales this year.

Skyrizi is not the first IL-23 to reach the market, but AbbVie claims it is the best, and boasts more convenient dosing once every three months. It will push for use as a first-line therapy and thanks to faster commercial access versus other recent launches in psoriasis, the company expects sales to reach around $150 million this year. Longer term there is a clear expectation for multi-billion dollar revenue.

With this in mind, our latest Physician Views snap-polling is asking US-based dermatologists the following questions…

____________

Q. Of the following treatment options, which would you currently consider your most frequently used standard-of-care therapy for moderate-to-severe plaque psoriasis?

An anti-TNF agent

Stelara (ustekinumab)

Cosentyx (secukinumab)

Taltz (ixekizumab)

Tremfya (guselkumab)

Illumya (tildrakizumab)

Otezla (apremilast)

-

Q. The FDA has approved Skyrizi (risankizumab), an interleukin-23 (IL-23) inhibitor, for the treatment of moderate-to-severe plaque psoriasis. 

The recommended dose for Skyrizi is 150mg, administered by two subcutaneous injections every 12 weeks following two initiation doses at week 0 and 4. Skyrizi can be administered in-office or by self-injection after training.

In the ultIMMa-1 and ultIMMa-2 studies at 16 weeks, PASI 90 was achieved in 75 percent of people treated with Skyrizi, compared to 5 percent and 2 percent receiving placebo, respectively. PASI 100 was achieved in 36 percent and 51 percent of people treated with Skyrizi, compared to 0 and 2 percent receiving placebo, respectively. At one year, 82 percent and 81 percent of people treated with Skyrizi achieved PASI 90, and 56 percent and 60 percent achieved PASI 100, respectively.

An integrated analysis of ultIMMa-1 and ultIMMa-2 showed most people treated with Skyrizi who achieved PASI 90 and PASI 100 at week 16 maintained this response at one year (88 percent and 80 percent, respectively).

Based on these data, how would you compare the efficacy profile of Skyrizi versus your current standard-of-care therapy for moderate-to-severe plaque psoriasis?

Much worse

Somewhat worse

About the same

Somewhat better

Much better

-

Q. The frequency of adverse events through one year was similar to events observed during the first 16 weeks. The most common adverse events associated with Skyrizi included upper respiratory infections (13 percent), headache (3.5 percent), fatigue (2.5 percent), injection site reactions (1.5 percent) and tinea infections (1.1 percent). Skyrizi requires an initial evaluation for tuberculosis (TB) prior to starting treatment, and patients are instructed to report signs and symptoms of infection.

Based on these data, how would you compare the safety profile of Skyrizi versus your current standard-of-care therapy for moderate-to-severe plaque psoriasis?

Much worse

Somewhat worse

About the same

Somewhat better

Much better

-

Q. Based on these clinical data and using a five point scale (where 1 = not willing to prescribe and 5 = very willing to prescribe), how willing will you be to prescribe Skyrizi during its first 12 months of launch?

-

Q. Based on these clinical data and using a five point scale (where 1 = not willing to prescribe and 5 = very willing to prescribe), how willing will you be to prescribe Skyrizi during its first 24 months of launch?

____________

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions.

Note: FirstWord Physician Views are a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties in major markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

Disclaimer: FirstWord follows market research best practices in conducting its Physician Views polls.  However, Physician Views results should be considered directional and clients should use their market research resources for statistical analysis and conclusions required with very high confidence levels.

To read more Physician Views articles, click here.